Mylan Laboratories Limited Actinomycin Export Data — India (DGFT 2022–2026)

Name: Mylan Laboratories Limited Actinomycin Export Records India — #2 Exporter, 4 Shipments, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Actinomycin

India Pharmaceutical Trade Intelligence

$2.9M184 Suppliers97 CountriesHS 30049046

ExportsIndia → UNITED STATES73.5%India → BRAZIL8.4%

ImportsUNITED STATES → India$114

#1 Supplier: EUGIA PHARMA #1 Buyer: EUGIA US

Mylan Laboratories Limited — Actinomycin Exporter #2 | $200.0K Trade Value | TransData Nexus | TransData Nexus

Mylan Laboratories Limited — Actinomycin Exporter Profile

Indian Pharmaceutical Exporter · #2 for Actinomycin · $200.0K export value · DGFT Verified

Mylan Laboratories Limited is the #2 Indian exporter of Actinomycin with $200.0K in export value and 4 verified shipments. Mylan Laboratories Limited holds a 6.8% market share in Actinomycin exports across 1 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.

Mylan Laboratories Limited — Actinomycin Export Profile: Buyers & Destinations

Mylan Laboratories Limited Actinomycin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Actinomycin?

Country	Value	Shipments	Share
UNITED STATES	$900.0K	18	63.1%
BRAZIL	$245.8K	324	17.2%
UGANDA	$37.6K	22	2.6%
ETHIOPIA	$36.0K	11	2.5%

Who Are the Top Buyers of Actinomycin from India?

Buyer	Country	Value	Orders
AUROLOGISTIC LLC	UNITED STATES	$200.0K	4
EUGIA US LLC	UNITED STATES	$150.0K	3
EUGIA US LLC,	UNITED STATES	$100.0K	2
ONCOPHARM SPECIALITY PHARMACY	UGANDA	$33.2K	3
ETHIOPIAN PHARMACEUTICALS	ETHIOPIA	$25.4K	2
TO THE	BRAZIL	$25.0K	33
EXP CODE	BRAZIL	$10.2K	11
TO THE MANAGER-	BRAZIL	$8.1K	2
TO THE,	BRAZIL	$7.9K	15

India's Actinomycin is purchased by 351 buyers worldwide. The top buyer is AUROLOGISTIC LLC (UNITED STATES), followed by EUGIA US LLC and EUGIA US LLC,.

How Does Mylan Laboratories Limited Compare to Nearest Actinomycin Exporters?

Exporters ranked immediately above and below #2 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	EUGIA PHARMA SPECIALITIES LIMITED	$250.0K	5	1	$50.0K
2	MYLAN LABORATORIES LIMITED ★	$200.0K	4	1	$50.0K
3	IKRIS PHARMA NETWORK PRIVATE LIMITED	$108.1K	103	1	$1.0K
4	CELON LABORATORIES PRIVATE LIMITED	$67.3K	16	10	$4.2K

Mylan Laboratories Limited ranks #2 among 184 Indian Actinomycin exporters. Average shipment value of $50.0K compared to the market average of $4.8K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and IKRIS PHARMA NETWORK PRIVATE LIMITED.

Which Indian Ports Ship Actinomycin Exports?

Port	Shipments	% Share
SAHAR AIR	304	32.6%
SAHAR AIR CARGO ACC (INBOM4)	184	19.7%
DELHI AIR	108	11.6%
Bombay Air	82	8.8%
DELHI AIR CARGO ACC (INDEL4)	62	6.6%
AHEMDABAD AIR	21	2.3%
Bombay Air Cargo	20	2.1%
Delhi Air	18	1.9%

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Actinomycin Exports

Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.

In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.

The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Actinomycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 97+ countries, 351+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Actinomycin

Actinomycin

Mylan Laboratories Limited — Actinomycin Exporter Profile

Mylan Laboratories Limited — Actinomycin Export Profile: Buyers & Destinations

Where Does India Export Actinomycin?

Who Are the Top Buyers of Actinomycin from India?

What Is India's Total Actinomycin Export Value and How Much Does Mylan Laboratories Limited Contribute?

What Is the Average Shipment Value for Mylan Laboratories Limited's Actinomycin Exports?

How Does Mylan Laboratories Limited Compare to Other Indian Actinomycin Exporters?

Regulatory Requirements: Exporting Actinomycin to Key Markets

United States — FDA

Brazil — ANVISA

How Does Mylan Laboratories Limited Compare to Nearest Actinomycin Exporters?

Which Indian Ports Ship Actinomycin Exports?

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Actinomycin Exports

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

About Mylan Laboratories Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Actinomycin Export Data from Mylan Laboratories Limited

Actinomycin Stats

Company Overview

Top Products by Mylan Laboratories Limited

Related Analysis

Need Detailed Export Data?

Data Source